UGT1A1 and chronic kidney disease: Plasma BR levels are known to be decreased in CKD.113 Clinical trials are needed in which plasma BR levels are increased through the inhibition of hepatic UGT1A1 or the use of BR nanoparticles (136) to determine the effectiveness of these approaches in combating the progression of CKD.